Tissue factor activity in patients with systemic lupus erythematosus: Association with disease activity

Journal of Rheumatology

Volumn 27, Issue 12, 2000, Pages 2827-2832

  Segal, J ^a   Kickler, T ^a   Petri, M ^a  

^a NONE   (United States)

Author keywords

Anticardiolipin antibodies; Systemic lupus erythematosus; Tissue factor

Indexed keywords

CARDIOLIPIN ANTIBODY; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; DNA ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPID ANTIBODY; THROMBOPLASTIN;

ADOLESCENT; ADULT; AGED; ANTIPHOSPHOLIPID SYNDROME; ARTHRITIS; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEDIMENTATION RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, ANTICARDIOLIPIN; ARTHRITIS; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; THROMBOPLASTIN; THROMBOSIS;

EID: 0033673047     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Pathogenesis and treatment of the antiphospholipid antibody syndrome
2. Production of IL-1beta, IL-1 receptor antagonist and IL-10 by mononuclear cells from patients with SLE
3. The frequency of lupus anticoagulant in systemic lupus erythematosus; a study of 60 consecutive patients by activated partial thromboplastin time, Russell viper venom time, and anticardiolipin antibody
4. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome
5. Effects of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor expression on monocytes
6. Thrombosis in primary antiphospholipid syndrome. A pivotol role for monocyte tissue factor expression
7. Upregulated tissue factor expression in antiphopholipid syndrome
8. Validity and reliability of lupus activity measures in the routine clinic setting
9. The development and validation of the SLE Disease Activity Index
10. Endotoxin stimulated whole blood clotting test for the measurement of tissue factor
11. Measurement of tissue factor expression in whole blood
12. A modified recalcificatiou time: A global screening test
13. The frequency of lupus anticoagulant in systemic lupus erythematosus; a study of 60 consecutive patients by activated partial thromboplastin time, Russell viper venom time, and anticardiolipin antibody
14. Robust estimation of a location parameter
15. Increased monocyte procoagulant activity independent of the lupus anticoagulant in patients with systemic lupus erythematosus
16. Antiphospholipid antibodies increase the potential monocyte procoagulant activity in patients with systemic lupus erythematosus
17. Sodium salicylate enhance expression of tissue factor in human adherent monocytes and in whole blood
18. Increased lipopolysaccharide-induced tissue factor activity and tumour necrosis factor production in monocytes after intake of aspirin; possible role of prostaglandin E2
19. Aspirin potentiates LPS-induced fibrin formation and TNF-alpha synthesis in whole blood
20. Salicylates inhibit lipopolysaccharide-induced transcriptional activation of the tissue factor gene in human monocytic cells
21. Acetylsalicylic acid and sodium salicylate inhibit LPS-induced NF-kappa B/c-Rel nuclear translocation and synthesis of tissue factor and tumor necrosis factor alpha in human monocytes
22. Hemoglobin, a newly recognized lipopolysaccharide-binding protein that enhances LPS biological activity
23. Hemoglobin enhances the binding of bacterial endotoxin to human endothelial cells